Overview of Targeted Therapy for Ovarian Cancer

What is Targeted Therapy for Ovarian Cancer?

Targeted therapy uses drugs to attack specific molecular weaknesses in ovarian cancer cells, thereby sparing normal tissues, unlike traditional chemotherapy. The primary agents in this approach are PARP inhibitors, which target DNA repair defects in high-grade serous ovarian cancer (HGSOC) associated with BRCA mutations or homologous recombination deficiency (HRD). Additionally, anti-angiogenic agents block the blood supply driven by VEGF.

Types of Targeted Therapy for Ovarian Cancer

• •PARP Inhibitors (Olaparib, Niraparib, Rucaparib)
  Used as oral maintenance therapy following platinum-based chemotherapy for advanced HGSOC, extending progression-free survival by 7 to 12 months in HRD-positive cases.
• •Anti-Angiogenic Agents (Bevacizumab)
  An intravenous monoclonal antibody that inhibits the growth of blood vessels; used in combination with chemotherapy for patients with stage III/IV or recurrent disease.
• •Other Specialized Agents
  MEK inhibitors (trametinib) for low-grade serous ovarian cancer; PI3K inhibitors for clear cell ovarian cancer; and immunotherapy (pembrolizumab) for MSI-high tumors.

When is Targeted Therapy Needed?

• •After Responding to First-Line Chemotherapy
  PARP inhibitors are recommended as maintenance therapy for all responders with stage III/IV HGSOC, regardless of BRCA status, based on trials like SOLO-1 and PAOLA-1.
• •For Platinum-Sensitive Recurrences
  Patients may be re-challenged with PARP inhibitors or receive bevacizumab plus carboplatin to extend the time to the next progression, guided by HRD testing.
• •For Rare Subtypes or Platinum-Resistant Disease
  MEK inhibitors benefit chemotherapy-resistant low-grade serous tumors, while clear cell tumors may qualify for PI3K/mTOR clinical trials and MSI-high cases for checkpoint inhibitors.

Treatment Process

Targeted therapies are administered either orally (daily PARP inhibitors) or intravenously (bevacizumab every three weeks) for 18 to 24 months. Monthly monitoring of complete blood count (CBC) and organ function is required. Genetic testing (Myriad myChoice CDx) is performed before treatment to determine HRD status, and outpatient administration allows patients to maintain their active lifestyles while managing potential side effects like cytopenias or hypertension.

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

Benefits and Risks

• •Key Benefits
  PARP maintenance can triple progression-free survival in BRCA-mutated cases (from 14 to 56 months). Bevacizumab adds an average of 3.5 months to progression-free survival while preserving quality of life compared to standard chemotherapy.
• •Side Effects and Risks
  PARP inhibitors may cause anemia (40%), nausea (75%), and fatigue. Bevacizumab carries risks of bowel perforation (2%), hypertension, and proteinuria. Rare risks include myelodysplastic syndrome (1.5%).

Aftercare and Recovery

To care for yourself during therapy, take PARP inhibitors with food and monitor blood pressure weekly if on bevacizumab. Quarterly CA-125 tests and CT scans are standard for monitoring treatment durability. Supplements like vitamin B12 and folate may counteract cytopenias, and patients should avoid NSAIDs while receiving bevacizumab to reduce risks. Maintaining proper nutrition is vital to sustain BMI during treatment.

Why Choose Everhope

Everhope Oncology provides comprehensive genomic profiling to enable personalized selection of PARP and anti-angiogenic therapies. On-site molecular tumor boards optimize treatment sequencing, and IV nutritional support is available to help mitigate symptoms like cytopenias.